HER2 status-Negative Posts on Medivizor
Navigation Menu

HER2 status-Negative Posts on Medivizor

Looking for patients with metastatic triple-negative breast cancer to trial experimental vaccine with biological therapy

Posted by on Sep 20, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...

Read More

Searching for patients with advanced triple-negative breast cancer to test a new combination treatment

Posted by on Aug 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...

Read More

Searching patients with triple-negative breast cancer to trial a new treatment combination

Posted by on Jul 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...

Read More

Looking for patients with advanced triple negative breast cancer to test a new drug

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced breast cancer and other solid tumors.  The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...

Read More

Searching for patients with advanced triple negative breast cancer to trial a new treatment into the tumor

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...

Read More

Searching for patients with triple negative breast cancer to test durvalumab and olaparib

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...

Read More

Searching for patients with triple negative breast cancer to test this new treatment combination

Posted by on May 19, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...

Read More

Looking for patients with estrogen receptor-positive breast cancer to test a new treatment combination

Posted by on May 11, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...

Read More

Searching for patients with triple negative breast cancer to test a new medication

Posted by on Apr 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 3 trial will investigate the safety and effectiveness of adagloxad simolenin (AGS)/OBI-821 in triple-negative breast cancer (TNBC). The main outcome will be a change in survival without invasive disease. The details Breast cancer (BC) is one of the most common cancers. BC treatment depends on the tumor type....

Read More